Research Article
Conversion Surgery for Patients with Advanced Gastric Cancer with Peritoneal Carcinomatosis
Table 1
Clinical characteristics of the patients.
| | Variable | NIPS | CRS + HIPEC | C/T | Palliative | | | (n = 34) | (n = 15) | (n = 23) | (n = 23) |
| | Age (y/o) | 65.3 (6.02) | 66.07 (10.19) | 65.91 (11.11) | 67.43 (9.05) | 0.850 | | Sex (male) | 17 (51.52%) | 8 (57.14%) | 16 (69.57%) | 15 (65.22%) | 0.536 | | Comorbidity | HTN | 7 (21.21%) | 6 (42.86%) | 10 (43.48%) | 12 (52.17%) | 0.095 | | CAD | 3 (9.09%) | 3 (21.43%) | 5 (21.74%) | 8 (34.78%) | 0.132 | | Diabetes | 1 (3.03%) | 3 (21.43%) | 6 (26.09%) | 5 (21.74%) | | | CVA | 1 (3.03%) | 1 (7.14%) | 2 (8.7%) | 1 (4.35%) | 0.751 | | ESRD | 0 (0%) | 0 (0%) | 1 (4.35%) | 3 (13.04%) | 0.077 | | Pulmonary | 2 (6.06%) | 1 (7.14%) | 2 (8.7%) | 1 (4.35%) | 0.999 | | (PS) ECOG | 0 (%) | 10 (30.3%) | 4 (28.57%) | 11 (47.83%) | 10 (43.48%) | 0.425 | | 1∼2 (%) | 21 (63.64%) | 9 (64.29%) | 12 (52.17%) | 10 (43.48%) | | >3 (%) | 2 (6.06%) | 1 (7.14%) | 0 (0%) | 3 (13.04%) | | VAS | 1.48 ± 0.97 | 1.21 ± 0.43 | 1.7 ± 1.11 | 2.09 ± 1.38 | | | TNM stage | T2 (%) | 2 (6.06%) | 0 (0%) | 3 (13.04%) | 6 (26.09%) | | | T3 (%) | 9 (27.27%) | 1 (7.14%) | 12 (52.17%) | 10 (43.48%) | | T4 (%) | 22 (66.67%) | 13 (92.86%) | 8 (34.78%) | 7 (30.43%) | | N1 (%) | 3 (9.09%) | 1 (7.14%) | 6 (26.09%) | 7 (30.43%) | | | N2 (%) | 17 (51.52%) | 6 (42.86%) | 3 (13.04%) | 7 (30.43%) | | N3 (%) | 7 (21.21%) | 7 (50%) | 11 (47.83%) | 9 (39.13%) | | Symptoms | Ascites (%) | 20 (60.61%) | 2 (14.29%) | 6 (26.09%) | 6 (26.09%) | | | Epigastric pain (%) | 33 (100%) | 13 (92.86%) | 22 (95.65%) | 20 (86.96%) | 0.128 | | UGI bleeding (%) | 11 (33.33%) | 4 (28.57%) | 7 (30.43%) | 10 (43.48%) | 0.746 | | Gastric outlet obstruction (%) | 7 (21.21%) | 10 (71.43%) | 8 (34.78%) | 8 (34.78%) | | | BW loss (%) | 18 (54.55%) | 3 (21.43%) | 13 (56.52%) | 15 (65.22%) | 0.068 | | Laboratory test | WBC (m/mm3) | 7080.91 ± 2516.55 | 7208.57 ± 3637.68 | 8513.48 ± 2849.05 | 9082.61 ± 4607.45 | 0.117 | | Hgb (g/dL) | 10.94 ± 2.87 | 10.37 ± 2.66 | 10.95 ± 2.76 | 10.22 ± 2.74 | 0.728 | | Sodium (mEq/L) | 137.12 ± 3.62 | 137.43 ± 3.11 | 135.57 ± 3.92 | 137.13 ± 2.44 | 0.260 | | Potassium (mmol/L) | 3.67 ± 0.42 | 3.94 ± 0.41 | 3.82 ± 0.45 | 3.87 ± 0.48 | 0.193 | | AST (U/L) | 19.42 ± 9.86 | 21.64 ± 10.3 | 41.74 ± 75.95 | 56.7 ± 94.08 | 0.154 | | Cr (mg/dL) | 0.75 ± 0.22 | 0.88 ± 0.18 | 1.07 ± 0.65 | 1.07 ± 0.64 | | | Albumin (g/dL) | 3.38 ± 0.56 | 3.46 ± 0.36 | 3.24 ± 0.48 | 3.06 ± 0.64 | 0.083 |
|
|
HTN, hypertension; CAD, coronary artery disease; CVA, cerebrovascular accident; ESRD, end-stage renal disease; PS (ECOG): patient performance (Eastern Cooperative Oncology Group); VAS: visual analog scale; UGI bleeding: upper gastrointestinal bleeding; BW loss: bodyweight loss; WBC: white cell count; AST: aspartate transaminase; Cr: creatinine; NIPS: neoadjuvant intraperitoneal and systemic chemotherapy; CRS + HIPEC: cytoreductive surgery + hyperthermic intraperitoneal chemotherapy; C/T: chemotherapy; Hgb: hemoglobin; <0.05. |
